Progenics Pharmaceuticals IncPGNX:NSQ

6.82
0.05 / 0.74%
665.27k
48.26%
1.56
Latest price in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Nov 24 2014 17:36 GMT.

Summary

As of last trade Progenics Pharmaceuticals Inc (PGNX:NSQ) traded at 6.82, 8.46% below its 52-week high of 7.45, set on Jan 17, 2014.

52-week range
Today
3.10
May 09 2014
7.45
Jan 17 2014
Markit short selling activity
Low
Medium
High
Open6.89
Day high7.10
Day low6.80
Bid6.82
Offer6.83
Previous close6.77
Average volume1.34m
Shares outstanding69.56m
Free float67.82m
P/E (TTM)142.32
Market cap470.89m USD
EPS (TTM)0.0476 USD
Data delayed at least 15 minutes, as of Nov 24 2014 17:36 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Progenics Pharmaceuticals Inc+6.73%+44.49%+84.32%+48.26%+66.34%
S&P 500 INDEX+1.09%+5.04%+8.57%+14.34%+86.63%
USA/HEALTH CARE+1.08%+4.40%+13.90%+19.37%--
USA/BIOTECHNOLOGY+1.50%-0.30%+22.70%+25.21%--
Data delayed at least 15 minutes, as of Nov 24 2014 17:36 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.